荧光图像引导手术在妇科恶性肿瘤的研究进展

doi:10.12280/gjfckx.20230638

摘要/Abstract

摘要：

荧光图像引导手术（fluorescence image-guided surgery，FIGS）是现代外科实践中的新兴技术，通过近红外荧光（near-infeared fluorecence，NIR）显像剂介导在手术中显影目的组织，作为实时、非侵入性和高分辨率的诊断方式，为手术医生提供屏幕图像，实现术中实时导航。FIGS在妇科恶性肿瘤可用于检测前哨淋巴结、淋巴造影、指示肿瘤边界、检测组织污染以及在手术中显影重要血管以评估血供等。由于NIR染料自身没有靶向性，与荧光染料结合的靶向分子探针正在被广泛研发并用于妇科恶性肿瘤的临床试验中，但假阳性率高仍是阻碍其临床应用的主要问题。随着新型荧光染料和成像系统的不断发展，FIGS可能会改变妇科恶性肿瘤的诊疗策略，为手术医生提供新的治疗选择。

关键词: 谱学, 近红外线, 荧光染料, 光学成象, 生殖器肿瘤, 女（雌）性, 诊断显像, 妇科外科手术, 切缘

Abstract:

Fluorescence image-guided surgery(FIGS) is a new technology in modern surgical practice, which uses near-infrared fluorescence(NIR) imaging agent to mediate the development of target tissue during surgery as a real-time, non-invasive and high-resolution diagnostic method to provide screen images for surgeons to achieve real-time intraoperative navigation. In gynecological malignant tumors, FIGS can be used to detect sentinel lymph nodes, perform lymphography, indicate tumor boundaries, detect tissue contamination and develop important blood vessels during surgery to evaluate blood supply. Due to the lack of targeting of NIR dye itself, targeted molecular probes combined with fluorescent dyes are being widely developed and used in clinical trials of gynecological malignant tumors. However, the high false positive rate is still the main problem hindering its clinical application. With the continuous development of new fluorescent dyes and imaging systems, FIGS may change the diagnosis and treatment strategy of gynecological malignant tumors and provide new treatment options for surgeons.

Key words: Spectroscopy, near-infrared, Fluorescent dyes, Optical imaging, Genital neoplasms, female, Diagnostic imaging, Gynecologic surgical procedures, Margins of excision

贾炎峰, 党云. 荧光图像引导手术在妇科恶性肿瘤的研究进展[J]. 国际妇产科学杂志, 2024, 51(1): 47-51.

JIA Yan-feng, DANG Yun. Progress of Fluorescence Image-Guided Surgery in Gynecological Malignant Tumors[J]. Journal of International Obstetrics and Gynecology, 2024, 51(1): 47-51.

参考文献 33

[1]	Yang SL, Si LH, Lin RX, et al. Prognostic role of the peritoneal cancer index in ovarian cancer patients who undergo cytoreductive surgery: a meta-analysis[J]. Curr Probl Cancer, 2023, 47(6):101014. doi: 10.1016/j.currproblcancer.2023.101014.
[2]	Matsuo K, Chen L, Robison K, et al. Trends in the use of indocyanine green for sentinel lymph node mapping in vulvar cancer[J]. Am J Obstet Gynecol, 2023, 229(4):466-468. doi: 10.1016/j.ajog.2023.07.019. pmid: 37454962
[3]	Nahshon C, Kadan Y, Lavie O, et al. Sentinel lymph node sampling versus full lymphadenectomy in endometrial cancer: a SEER database analysis[J]. Int J Gynecol Cancer, 2023, 33(10):1557-1563. doi: 10.1136/ijgc-2023-004474.
[4]	Uccella S, Nero C, Vizza E, et al. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY)[J]. Am J Obstet Gynecol, 2019, 221(4):324.e1-e10. doi: 10.1016/j.ajog.2019.05.005.
[5]	Agusti N, Viveros-Carreño D, Grillo-Ardila C, et al. Sentinel lymph node detection in early-stage ovarian cancer: a systematic review and meta-analysis[J]. Int J Gynecol Cancer, 2023, 33(10):1493-1501. doi: 10.1136/ijgc-2023-004572.
[6]	Terada S, Tanaka T, Murakami H, et al. Lymphatic Complications Following Sentinel Node Biopsy or Pelvic Lymphadenectomy for Endometrial Cancer[J]. J Clin Med, 2023, 12(13):4540. doi: 10.3390/jcm12134540.
[7]	Berasaluce Gómez A, Martín-Calvo N, Boria F, et al. SUCCOR Nodes: May Sentinel Node Biopsy Determine the Need for Adjuvant Treatment?[J]. Ann Surg Oncol, 2023, 30(8):4975-4985. doi: 10.1245/s10434-023-13529-w.
[8]	Ramirez PT, Frumovitz M, Pareja R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer[J]. N Engl J Med, 2018, 379(20):1895-1904. doi: 10.1056/NEJMoa1806395.
[9]	Klapdor R, Hertel H, Hillemanns P, et al. Peritoneal contamination with ICG-stained cervical secretion as surrogate for potential cervical cancer tumor cell dissemination: A proof-of-principle study for laparoscopic hysterectomy[J]. Acta Obstet Gynecol Scand, 2019, 98(11):1398-1403. doi: 10.1111/aogs.13681.
[10]	Nguyen-Xuan HT, Montero Macias R, Bonsang-Kitzis H, et al. Use of fluorescence to guide surgical resection in vulvo-vaginal neoplasia: Two case reports[J]. J Gynecol Obstet Hum Reprod, 2021, 50(6):101768. doi: 10.1016/j.jogoh.2020.101768.
[11]	Escobar PF, Ramirez PT, Garcia Ocasio RE, et al. Utility of indocyanine green (ICG) intra-operative angiography to determine uterine vascular perfusion at the time of radical trachelectomy[J]. Gynecol Oncol, 2016, 143(2):357-361. doi: 10.1016/j.ygyno.2016.08.239. pmid: 27544455
[12]	姚瑶, 龙颖, 卢艳, 等. ICG血管显像在保留子宫动脉输尿管分支宫颈癌根治术中的应用[J]. 肿瘤防治研究, 2019, 46(2):193-194. doi: 10.3971/j.issn.1000-8578.2019.18.0284.
[13]	Höckel M, Hentschel B, Horn LC. Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis[J]. Lancet Oncol, 2014, 15(4):445-456. doi: 10.1016/S1470-2045(14)70060-9. pmid: 24656439
[14]	Kimmig R, Iannaccone A, Aktas B, et al. Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy[J]. Arch Gynecol Obstet, 2016, 294(1):153-160. doi: 10.1007/s00404-015-3956-y. pmid: 26596725
[15]	Gentileschi S, Albanese R, Servillo M, et al. Pedicled neurocutaneous anterolateral thigh flap for groin reconstruction-A case report[J]. Microsurgery, 2019, 39(5):447-451. doi: 10.1002/micr.30454. pmid: 30957283
[16]	Kreklau A, Lopez Benitez R, Fornaro J, et al. Computer Tomography-Guided Percutaneous Indocyanine Green Injection for Intraoperative Mapping of Metastatic Suspected Lesions[J]. Front Med(Lausanne), 2018, 5:191. doi: 10.3389/fmed.2018.00191.
[17]	Tummers QR, Hoogstins CE, Peters AA, et al. The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer[J]. PLoS One, 2015, 10(6):e0129766. doi: 10.1371/journal.pone.0129766.
[18]	van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results[J]. Nat Med, 2011, 17(10):1315-1319. doi: 10.1038/nm.2472. pmid: 21926976
[19]	Hoogstins CE, Tummers QR, Gaarenstroom KN, et al. A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer[J]. Clin Cancer Res, 2016, 22(12):2929-2938. doi: 10.1158/1078-0432.CCR-15-2640. pmid: 27306792
[20]	Randall LM, Wenham RM, Low PS, et al. A phase Ⅱ, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer[J]. Gynecol Oncol, 2019, 155(1):63-68. doi: 10.1016/j.ygyno.2019.07.010. pmid: 31362825
[21]	Tanyi JL, Randall LM, Chambers SK, et al. A Phase Ⅲ Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)[J]. J Clin Oncol, 2023, 41(2):276-284. doi: 10.1200/JCO.22.00291.
[22]	Boogerd L, Hoogstins C, Gaarenstroom KN, et al. Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study[J]. Oncotarget, 2018, 9(1):791-801. doi: 10.18632/oncotarget.23155. pmid: 29416655
[23]	Voskuil FJ, Steinkamp PJ, Zhao T, et al. Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery[J]. Nat Commun, 2020, 11(1):3257. doi: 10.1038/s41467-020-16814-4. pmid: 32591522
[24]	García de Jalón E, Kleinmanns K, Fosse V, et al. Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model[J]. Mol Imaging Biol, 2023, 25(1):144-155. doi: 10.1007/s11307-021-01685-y.
[25]	Kleinmanns K, Fosse V, Davidson B, et al. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model[J]. EBioMedicine, 2020, 56:102783. doi: 10.1016/j.ebiom.2020.102783.
[26]	Fung K, Sharma SK, Keinänen O, et al. A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer[J]. Mol Pharm, 2020, 17(8):3140-3147. doi: 10.1021/acs.molpharmaceut.0c00437.
[27]	Chen J, Zhang C, Guo Y, et al. Evaluation of a novel ovarian cancer-specific fluorescent antibody probe for targeted near-infrared fluorescence imaging[J]. World J Surg Oncol, 2020, 18(1):66. doi: 10.1186/s12957-020-01843-6. pmid: 32252772
[28]	Zhang C, Ling X, Guo Y, et al. Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging[J]. Chin J Cancer Res, 2019, 31(4):673-685. doi: 10.21147/j.issn.1000-9604.2019.04.11.
[29]	Liu Q, Zhou X, Feng W, et al. Gonadotropin-Releasing Hormone Receptor-Targeted Near-Infrared Fluorescence Probe for Specific Recognition and Localization of Peritoneal Metastases of Ovarian Cancer[J]. Front Oncol, 2020, 10:266. doi: 10.3389/fonc.2020.00266. pmid: 32185134
[30]	Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies[J]. J Nucl Med, 2011, 52(11):1778-1785. doi: 10.2967/jnumed.111.092833.
[31]	Huisman BW, Cankat M, Bosse T, et al. Integrin αvβ6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions[J]. Cancers(Basel), 2021, 13(23):6006. doi: 10.3390/cancers13236006.
[32]	Shaw SK, Schreiber CL, Roland FM, et al. High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors[J]. Bioorg Med Chem, 2018, 26(8):2085-2091. doi: 10.1016/j.bmc.2018.03.007.
[33]	Wang P, Fan Y, Lu L, et al. NIR-Ⅱ nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer[J]. Nat Commun, 2018, 9(1):2898. doi: 10.1038/s41467-018-05113-8.